Liquidia shares jump 11% on court ruling

8 October 2024

Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorble court ruling.

The firm earlier announced that the US Supreme Court has rejected United Therapeutics’ (Nasdaq: UTHR) petition for a writ of certiorari, which requested permission to appeal prior decisions which found that all claims of US Patent No. 10,716,793 (‘793 Patent) are unpatentable due to prior art.

This means that the decision by the Patent Trial and Appeal Board (PTAB) in July 2022, which was affirmed by the US Court of Appeals for the Federal Circuit (Federal Circuit) in December 2023, is now final and not subject to further appeal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK